Labs/Biomarkers

What can we learn from large IgG4 dataset? Epic Cosmos reviewed for IgG4 ICD codes Total: 6.4k IgG4-RD & 128k matched controls IgG4 patients: - more HTN, HLD, DMII - more MI, CVA, VTE - more infections - higher incident malignancy @RheumNow #ACR26 #ABST2108 https://t.co/7mUOItGONP

https://x.com/Dr_Brian_MD/status/2120210577112887732/photo/1

Jamaly et al investigated P-selectin glycoprotein ligand-1 as a noninvasive marker of lupus nephritis, with multi-institutional validation. Could we detect renal inflammation earlier and reduce reliance on biopsy? @rheumnow #ACR2026 Abstract#LB06

ACR26 Abstract #2243: Can AI see more in an ANA image than we do? Deep-learning models predicted several specific autoantibodies directly from HEp-2 immunofluorescence images, including anti-dsDNA with an AUC of 0.902. Exciting potential for laboratory triage @RheumNow

Myositis is not always “painless weakness.” #ACR26 Abstract 2825: survey of 552 pts with IIM + pain. Mean pain was 4.6/10, rising to 7.4 during flares; 77% reported persistent pain. Low back 78%, neck 72% and upper legs 72% were most affected. Ask about pain. @RheumNow https://t.co/2J7y4WA0F7

https://x.com/bella_mehta/status/2120197778240418271/photo/1

Pregnancy in SLE still carries major risk: early preterm birth 10.3% vs 2.8% and preeclampsia 15.6% vs 6.7% in >11M pregnancies- 3,950 lupus ones. Lupus nephritis identifies an especially high-risk group needing preconception planning. @rheumnow #ACR26 Abstract #2462 https://t.co/7PDZrAW15w

https://x.com/bella_mehta/status/2120195026299003142/photo/1

Lupus nephritis is more than immune-complex inflammation. TREM2+/SPP1+ macrophages localized near mesangial cells and myofibroblasts and signaled through SPP1/TGF-β, linking macrophages to fibrotic reprogramming. @rheumnow #ACR26 Abstract #1905 https://t.co/uqsYvi7dc9

https://x.com/bella_mehta/status/2120191284778508547/photo/1

Study on ADAs fr ROC-SpA cohort: 21% had ADA against 1st TNFi. ADA+ against 1st TNFi assoc'd w/ higher likelihood of clinical response to subsequent tx Reasons for Tx d/c of 1st TNFi & ADA+: Strong assoc bet ADA+ & secondary non-response (p=0.002) @RheumNow #ACR26 Abs2284 https://t.co/TBTEgL5OFx

This prospective observational study on NPSLE pts showed that delirium was assoc'd w/ myositis, LN, vasculitis and seizures. Active lupus dse was seen in NPSLE pts w/ delirium vs. those w/o. Delirium correlated w/ higher antidsDNA levels & low C4 @RheumNow #ACR26 Abs2244 https://t.co/6MKWNAuN9g

https://x.com/RHEUMarampa/status/2120189992928411716/photo/1

What if we could identify SLE BEFORE clinical disease develops? New longitudinal proteomic research reveals distinct molecular trajectories preceding SLE progression. Could a future blood test help distinguish pts at risk from those who may never develop lupus? #1821 @RheumNow

Can we finally agree on what makes an SI joint MRI “positive” for axial SpA? New SPARTAN/SSR framework incorporates inflammatory AND structural lesions, achieving 81–96% sensitivity and 90–98% specificity across 3 cohorts. A major step toward MRI clarity! #1825 @RheumNow #ACR26

Important post hoc of RITAZAREM study (RTX vs AZA in AAV) Off-maintenance study of pts who completed study; higher relapse free survival in RTX at 6 mos (95% vs 72% AZA, NNT ~5) & 12 mos (82% vs 61%) Detectable antibodies predicted RTX failures (HR 8.2), ANCA positivity in AZA https://t.co/VvUL5Xmccr

Lupus nephritis: prognostic value of biopsy timing & histology Abst 2269: • Biopsy >90d from first LN sign: dec. odds of complete/partial renal response at 1y (aOR 0.30) • Chronicity >3: inc. odds CKD/ESKD/transplant at 1y • Activity >10: inc. odds ESKD #ACR26 @RheumNow https://t.co/20GeZCJWBD

Does apremilast work in early PsA? Pooled data from 7 trials (n=943, disease duration ≤2 years) show significant wk 16 gains in ACR response, cDAPSA, enthesitis and PROs, but not dactylitis. What of with longer-duration disease? A#2293 @RheumNow #ACR26 https://t.co/eYPSu0x0H2

https://x.com/JihaRheum/status/2120181436875432414/photo/1

What is the efficacy of enaptoran (TLR7/8 inhibitor) in SLE? Abstract 2202 Phase 2 WILLOW study: enaptoran v placebo - Improved BILAG MSK score - Greater reduction in >50% tender/swollen joint - significant diff in BICLA response in pts w MSK nad skin @RheumNow #ACR26 https://t.co/3Lv2Spga0K

https://x.com/AkhilSoodMD/status/2120180429915644275/photo/1

Risk stratification in pulm sarcoidosis- AB#2805 #ACR26 @RheumNow Predictors of radiologic progression, Rx escalation: -Symptom burden incl dyspnea -Systemic inflamm incl CRP -Extrapulm CT involvement These are STRONGER predictors than PET activity- limited prognostic value https://t.co/MGSbxExB5e

Placental lesions assoc w/ adverse preg outcomes (APO) in SLE: 44/57 had APOs (preterm, preec, SGA) Placentas of SLE w/ APOs vs. SLE w/o APO: Higher maternal vasc malperfusion (MVM) [77 vs 31% p0.005)] predominantly the AVM phenotype (64 vs 15% p0.004) @RheumNow #ACR26 Abs2461 https://t.co/HYOdUUztbs

https://x.com/RHEUMarampa/status/2120178165444395036/photo/1

The Usual Suspects: Unmasking Difficult-to-Treat RA #ACR26: IgA-MAA emerged as an independent predictor of D2T-RA, while adipokines showed predictive potential in patients with obesity. The clues may lie beyond clinical factors. @RheumNow https://t.co/g6TGguXggs

https://x.com/Mota_licia_reum/status/2120176208390553910/photo/1

Symptom-Inflammation Phenotypes in Active RA Data from CPIRA cohort (n=283, established active RA), used K-means clustering on PROs + inflammatory markers (SJC28, hsCRP) to find phenotypes. Identified 4 clusters: -C1 (n=117): low-moderate inflammation, low symptoms -C2 (n=77): https://t.co/s8wCEtj3iI

Article

Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA

Adela Castro, MD Nov 10, 2026

14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA pathogenesis (1). There is little evidence on its expression in patients with

Can gut #candida trigger #rheumatoid #arthritis? ⬆️candida #albicans gut #microbiome in RA & at-risk RA ⬆️IgA candida in gu Insufficient to cause #IA in mice But silent immune priming ⬆️risk of #arthritis in mice w other hit? Alters TH17 #ACRbest #2832 #ACR26 @ACRheum @RheumNow https://t.co/L3Nva3vzXM

Prevalence of ANCA in SLE & LN: 33% in SLE pts w/ +ANCA and had incr odds of LN, low C3 &/or C4, +anti-Sm 19% in LN pts w/ +ANCA and had incr odds of myositis & photosensitivity; anti-dsDNA & ANA ANCA+ in SLE can help predict symptoms & renal involv’t @RheumNow #ACR26 Abs2236 https://t.co/8YlgYCeMGQ

A#2826 @RheumNow #ACR26 Transcriptional profile of circulating monocytes assoc w nociplastic pain in RA Key pathways: - NFkB correlates w high pain sensitization - Macrophage activation corr PROMIS pain - Cytokine production LOWER PROMIS fatigue Further study IFN sig w pain sens https://t.co/AVvQLgUPLT

https://x.com/ericdeinmd/status/2120157938845159882/photo/1

Could blood proteins guide JAKi vs TNFi selection? A 7-protein model discriminated opposite 6-month remission outcomes in advanced-therapy-naive RA (AUC 0.75), but performed poorly after prior therapy (0.57). @Rheumnow #2829 #ACR26

Interim analysis from ReBIOLup study by Dr @IoannisParodis show a discordance bet UPCR and activity index on repeat biopsy of LN pts 14.9% w/UPCR <0.5 g/g & NIH AI ≥4 10.6% w/UPCR >1 g/g & NIH AI < 3 Proteinuria not entirely reflective of dse act. @RheumNow #ACR26 Abs1862 https://t.co/SgZmLF6Dz9

https://x.com/RHEUMarampa/status/2119998064580608257/photo/1

#LN cohort Rx w #belimumab DR M Petri observe LN study Showing #preservation of #renal #function w #BEL ☑️partial and complete in 61 pts Renal responses in real world data mirroring the #RCT data #CRR #PRR 87.5 CRR to 94% PRR at 2y #ACR26 #1229 @ACRheum @RheumNow https://t.co/b2XkqawOVl